February 27, 2009
Whom It May Concern
KYORIN Co., Ltd.
5, Kanda Surugadai 2-chome,Chiyoda-ku, Tokyo
Securities code; 4569, TSE 1st Section

Execution of Licensing and Supply Agreement on Uritos® Tablets with SPIMACOKYORIN Co., Ltd. announces that its wholly owned subsidiary, KYORIN Pharmaceutical Co.,
Ltd. (Head office: Tokyo, President: Itaru Kojo) has entered into a License and Supply Agreementwith Saudi Pharmaceutical Industries & Medical Appliances Corporation ("SPIMACO") (Headoffice: Riyadh, Saudi Arabia, President: Dr. Abdullah Bin Abdulaziz Al Abdulkader), under which
KYORIN Pharmaceutical granted to SPIMACO an exclusive right to develop, register, import,and market Uritos® Tablets (generic name: Imidafenacin), a therapeutic agent for overactive
bladder (OAB) in thirteen countries in the Middle East and North Africa (MENA) region,including Saudi Arabia.
Uritos® Tablets is an anticholinergic agent exerting selective antagonist actions on M3 and M1
muscarinic subtype receptors and improves urgency, urinary frequency and urge urinary
incontinence associated with OAB, which has a characteristic safety profile, such as low incidenceof dry mouth due to its high selective actions on the bladder. In Japan, KYORIN Pharmaceuticaland Ono Pharmaceutical Co., Ltd. are currently marketing this agent under the brand names ofUritos® Tablets and Staybla® Tablets respectively (launched in June 2007).
Taking this alliance opportunity with SPIMACO, a leading pharmaceutical company in Saudi
Arabia, with Uritos® Tablets which is KYORIN's first product expected to be launched in theregion, KYORIN Pharmaceutical wishes to spread its global business activities.
KYORIN Pharmaceutical is to be contributing to OAB patients by means of improvement of their
quality of life through early penetration of Uritos® Tablets into the Japanese market.
###Contacts:
Management Planning Department
K Y O R I N
C o . ,L t d .
T E L :
3 - 3 2 9 3 - 3 4 1 4
F A X :
3 - 3 2 9 3 - 3 4 5 4

About SPIMACO
Foundation:
President:
Revenue:
Employees:
Features:

January 1986
Dr. Abdullah Bin Abdulaziz Al Abdulkader
SAR 872 million (2008)
972 (as of December 31, 2008)
SPIMACO is the No.1 local pharmaceutical company and listed in Saudi
stock market. It has developed a strong position in the urology field.
SPIMACO has established various business partnerships with multinational
pharmaceutical/biotech companies. For more information, visit
http://www.spimaco.com.sa/eindex.htm.

About KYORIN Pharmaceutical
Foundation:
December 1923
President and CEO: Itaru Kojo
Revenue:
JPY 70.5 billion (March 31, 2008)
Employees:
1,517 (as of March 31, 2008)
Features:

KYORIN Pharmaceutical is aiming at its corporate vision of becoming an
integrated, trusted and unique healthcare organization based on global drug
discovery operations. It is pursuing evolution of its drug discovery
business model and establishment of new operations which may support its
drug discovery business. KYORIN Pharmaceutical is focusing its
marketing efforts and resources on the fields of respiratory, otolaryngology
and urology, and its R&D efforts and resources on the areas of infectious,
immunological/allergic and metabolic diseases. For more information,
visit http://www.kyorin-pharm.co.jp/en/.